Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
If you or a loved one has been diagnosed with dementia, a free service called TrialMatch can help you find experimental treatments being tested specifically for your situation. TrialMatch is a clinical trial matching service operated by the Alzheimer’s Association that has connected more than 370,000 people with dementia, caregivers, and healthy volunteers to clinical research studies since its launch in July 2010. It works by having users answer 10 simple questions online, after which the system provides personalized matches to studies across treatment, prevention, and care approaches—with no cost for the study treatment, related medical tests, or study visits.
This article covers how TrialMatch operates, what alternatives exist, what types of studies are available, how to access these services, important limitations to understand, and the emerging dementia treatments currently being tested through clinical trials. The appeal of clinical trial participation for dementia patients is significant. While approved medications like Leqembi and Kisunla have made recent advances possible, participating in trials gives access to experimental treatments that may not yet be available through standard medical care. Many patients wait years to benefit from new therapies, but trial enrollment can provide access to the most cutting-edge options months or even years earlier.
Table of Contents
- How Does TrialMatch Help Connect Dementia Patients to Clinical Studies?
- What Other Options Exist Besides TrialMatch?
- What Types of Clinical Studies Are Available for Dementia Patients?
- What Are the Practical Steps to Getting Started with TrialMatch?
- What Are the Important Limitations and Barriers to Consider?
- What Recent Dementia Treatments Are Being Tested or Have Recently Reached Approval?
- What Does the Future of Dementia Clinical Trials Look Like?
- Conclusion
How Does TrialMatch Help Connect Dementia Patients to Clinical Studies?
TrialMatch operates as a straightforward matching system that requires minimal effort from participants. Users or their caregivers log onto the service and respond to approximately 10 questions about their health status, location, and situation. The platform then searches a database containing hundreds of pharmacological and non-pharmacological studies to identify opportunities that fit their profile. Once matches are identified, TrialMatch provides referrals directly to the research sites, giving people a concrete starting point for enrollment.
The scale of TrialMatch’s reach demonstrates its importance in connecting people to research. The service has recorded 122,461 web sessions and provided 17,725 referrals in recent tracking periods. However, the broader context matters: at any given time, an estimated 1,867,403 participants are needed across all ongoing U.S. dementia studies, indicating that while TrialMatch successfully matches thousands of people, the research community still faces significant recruitment challenges. This means that qualified participants willing to enroll have a reasonably good chance of finding appropriate studies in their area.
What Other Options Exist Besides TrialMatch?
The National Institute on Aging offers a complementary resource called Alzheimers.gov Clinical Trials Finder, a government-sponsored free tool run directly by the federal government. Like TrialMatch, it helps people locate clinical trials for dementia and memory issues, and it also offers support through the same channels—800-438-4380 or email contact. However, there are practical differences worth considering. TrialMatch’s 10-question format is designed to be quick and user-friendly, while Alzheimers.gov may require more detailed information entry depending on the search approach.
The main advantage of having multiple services is redundancy; a study that appears in one database might not immediately appear in another, so checking both increases the likelihood of finding all locally available opportunities. One important limitation: not every study that meets someone’s profile will be recruiting actively. A trial might appear in the database but could be closed to new enrollment or focused on a specific demographic that seems to match but has additional unstated requirements. This is why TrialMatch and other services provide referrals to the actual research site rather than guaranteeing enrollment. The participant or their caregiver then contacts the study team directly to confirm eligibility and availability.
What Types of Clinical Studies Are Available for Dementia Patients?
The clinical trial database covers three broad categories: pharmacological treatment studies, non-pharmacological intervention studies, and prevention studies. Pharmacological trials test new medications—such as the recent wave of amyloid-targeting drugs—for safety and effectiveness in slowing cognitive decline or improving symptoms. Non-pharmacological studies might examine cognitive training programs, lifestyle interventions, caregiving support approaches, or even dietary modifications that could affect brain health. Prevention-focused trials recruit people with mild cognitive impairment or those without symptoms but at genetic risk for dementia, testing whether early intervention can delay or prevent disease onset altogether.
The sheer diversity of the trial landscape has expanded dramatically in recent years. Currently, nearly 200 clinical trials are underway assessing 150 or more novel drugs for dementia-related conditions. This includes 138 drugs being tested across 182 clinical trials specifically for Alzheimer’s disease alone. The breadth of options means that participants have a genuine range of study types to choose from depending on their disease stage, preferences, and location.
What Are the Practical Steps to Getting Started with TrialMatch?
The first step is to contact TrialMatch directly through their website or by phone at 800.272.3900 or email at [email protected]. If you prefer working through the government resource, Alzheimers.gov has similar contact options and a web interface for searching. When you reach out, have basic information ready: your diagnosis or the type of condition you’re interested in studying, your location (or willingness to travel), and whether you’re a patient, caregiver, or healthy volunteer interested in research. The 10-question assessment typically takes just a few minutes to complete.
Once matches are provided, the next practical consideration is feasibility. Some trials require frequent visits to research centers, which may not be realistic for someone with advanced dementia or limited mobility. Others offer remote participation or fewer in-person visits. The trial referral will include details about time commitment and location, allowing you to realistically assess whether the study fits your life. Some trials even reimburse travel expenses, which can make participation more feasible for those traveling to research sites.
What Are the Important Limitations and Barriers to Consider?
Not everyone qualifies for every trial, and eligibility criteria can be surprisingly restrictive. Trials testing medications for early Alzheimer’s disease, for example, often require participants to be within a specific stage of cognitive decline—too early and people don’t have enough decline to measure benefit; too late and advanced disease could complicate safety monitoring. Similarly, trials may exclude people taking certain medications or with specific medical conditions, even if those conditions seem unrelated to dementia. A person with well-controlled diabetes or hypertension might still be excluded from a particular study, sometimes for unclear reasons.
Another limitation relates to uncertainty about which trials are best suited to which patients. The system provides matches, but there’s no guarantee that the trial team will accept your referral, and there’s no way to know in advance which treatment approach might be most beneficial for your specific situation. Unlike approved medications with a clear track record of effectiveness, experimental treatments are unproven—that’s the nature of clinical research. Some trials will show no benefit, some will be stopped for safety concerns, and some will eventually support FDA approval of new treatments. Participants are taking on the unknown for the possibility of helping themselves and contributing to medical science.
What Recent Dementia Treatments Are Being Tested or Have Recently Reached Approval?
The landscape of dementia treatment has accelerated dramatically since 2024. Leqembi (lecanemab) has become the first monoclonal antibody to slow cognitive decline in early Alzheimer’s disease, and the FDA recently approved a new formulation in August 2025—LEQEMBI IQLIK™—as a weekly subcutaneous injection that patients can self-administer at home. This represents a significant practical improvement over the original IV infusion format. The FDA also approved a maintenance schedule of IV dosing every four weeks on January 26, 2025, giving patients flexibility in how they receive treatment.
Another approved drug, Kisunla (donanemab), has also received updated dosing regimens designed to reduce side effects while maintaining efficacy in reducing amyloid accumulation in the brain. Looking ahead, the FDA is expected to issue decisions on three additional dementia drugs in 2026, including Axsome’s AXS-05 for treating agitation in Alzheimer’s patients—a decision expected by April 30, 2026. These drugs represent the cutting edge of the research pipeline, many of which have been tested through the same clinical trial systems that TrialMatch connects people to. For someone considering trial participation, understanding that recent trial participants helped establish safety and efficacy data for treatments now reaching approval can be motivating; the time invested in research today might contribute to treatments available to others tomorrow.
What Does the Future of Dementia Clinical Trials Look Like?
With nearly 200 trials ongoing and a robust pipeline of experimental drugs, the next several years will likely bring significant changes to dementia treatment options. The shift toward earlier intervention—testing drugs in people with mild cognitive impairment or even before symptoms appear—suggests that future clinical trials will increasingly focus on prevention as well as treatment. This could expand participation opportunities for healthy individuals with genetic risk factors or early cognitive changes that don’t yet qualify as dementia.
The regulatory environment also appears to be evolving. The FDA has approved multiple disease-modifying treatments in rapid succession, signaling that approval pathways for dementia drugs may accelerate in the coming years. This could mean more treatment options reaching availability faster, which makes clinical trial participation increasingly valuable both for individual patients seeking access to cutting-edge approaches and for the research enterprise as a whole trying to keep pace with advancing science.
Conclusion
TrialMatch and similar clinical trial matching services provide a concrete pathway for dementia patients, caregivers, and healthy volunteers to access experimental treatments at no cost while contributing to medical research. The service has successfully connected hundreds of thousands of people to studies since its inception, and the breadth of available trials continues to expand. If you’re interested in participation, contacting TrialMatch at 800.272.3900 or [email protected] is the logical first step.
However, trial participation requires realistic expectations about eligibility, time commitment, and outcomes. Not every matched trial will accept you, not every trial will prove beneficial, and experimental treatments carry unknown risks. Yet for people living with dementia or those at risk, clinical trials offer something standard care cannot: early access to treatments that may eventually transform dementia management, paired with the knowledge that you’re directly contributing to the science that helps future patients. The momentum in dementia research is real and accelerating, and participants in today’s trials are making that progress possible.
You Might Also Like
- The Support Group for Spouses of Dementia Patients That Now Has 50,000 Members Nationwide
- The Non Drug Intervention That Reduced Agitation in Dementia Patients by 50%
- The First Responder Training Program That Teaches Police How to Interact With Dementia Patients
For more, see National Institute on Aging.
